[go: up one dir, main page]

MX2012014983A - Quinolinas como inhibidores pi3k. - Google Patents

Quinolinas como inhibidores pi3k.

Info

Publication number
MX2012014983A
MX2012014983A MX2012014983A MX2012014983A MX2012014983A MX 2012014983 A MX2012014983 A MX 2012014983A MX 2012014983 A MX2012014983 A MX 2012014983A MX 2012014983 A MX2012014983 A MX 2012014983A MX 2012014983 A MX2012014983 A MX 2012014983A
Authority
MX
Mexico
Prior art keywords
inflammatory
disorders
inhibitors
quinolines
phosphatidylinositol
Prior art date
Application number
MX2012014983A
Other languages
English (en)
Inventor
Paul John Dransfield
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2012014983A publication Critical patent/MX2012014983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos que tienen la estructura: (ver Fórmulas) que son inhibidores selectivos de PI3K (fosfatidilinositol 3-cinasa-delta), para fabricar medicamento útil para reducir de inflamación general, artritis, enfermedades reumáticas, osteoartritis, trastornos inflamatorios del intestino, trastornos inflamatorios del ojo, trastornos de la vejiga inestables o inflamatorios, psoriasis, dolencias de la piel con componentes inflamatorios, afecciones inflamatorias crónicas.
MX2012014983A 2010-06-30 2011-06-30 Quinolinas como inhibidores pi3k. MX2012014983A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36026210P 2010-06-30 2010-06-30
PCT/US2011/042531 WO2012003278A1 (en) 2010-06-30 2011-06-30 Quinolines as p13k inhibitors

Publications (1)

Publication Number Publication Date
MX2012014983A true MX2012014983A (es) 2013-04-24

Family

ID=44359353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014983A MX2012014983A (es) 2010-06-30 2011-06-30 Quinolinas como inhibidores pi3k.

Country Status (7)

Country Link
US (1) US8686137B2 (es)
EP (1) EP2588477A1 (es)
JP (1) JP2013530239A (es)
AU (1) AU2011272857A1 (es)
CA (1) CA2803619A1 (es)
MX (1) MX2012014983A (es)
WO (1) WO2012003278A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
PE20170640A1 (es) 2014-07-04 2017-05-26 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2132545B1 (es) * 1971-04-08 1974-08-02 Roussel Uclaf
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE3020458C2 (de) 1980-05-29 1986-07-31 Herzog, Thomas, Prof. Dr., 3500 Kassel Vorgehängte Fassaden-, Bau- oder Dekorationsplatte
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5822910A (en) 1997-10-02 1998-10-20 Shewmake; I. W. Fishing line tensioning device
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US8703778B2 (en) * 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
GB0821693D0 (en) 2008-11-27 2008-12-31 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
EP2588477A1 (en) 2013-05-08
CA2803619A1 (en) 2012-01-05
WO2012003278A1 (en) 2012-01-05
US20130143882A1 (en) 2013-06-06
AU2011272857A1 (en) 2013-01-10
US8686137B2 (en) 2014-04-01
JP2013530239A (ja) 2013-07-25

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
AU2018236800B2 (en) DNA-PK inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
GEP20156229B (en) 5-alkynyl-pyrimidines
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
MY182095A (en) Autotaxin inhibitor compounds
UA112795C2 (uk) Біциклічні піразинонові похідні
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
EP3047024A4 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
CL2013000455A1 (es) Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
ME03073B (me) Ant agonisti il17с za lečenje zapaljenskih poremećaja
WO2012065139A3 (en) Entpd5 inhibitors
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EP3035992A4 (en) Compositions, methods and systems for the treatment of cutaneous disorders
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
LT3495495T (lt) Diagnostiniai žymenys ląstelių proliferacijos sutrikimų gydymui telomerazės inhibitoriais
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
CA2887539C (en) Azaquinazoline carboxamide derivatives
MX364859B (es) Derivados de imidazopirazinona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal